Sugi Predict

Sugi Predict / Compounds / SCHEMBL1768281

SCHEMBL1768281

SCHEMBL1768281

C[C@H](NC(Cc1ccc(-c2cc(Cl)ccc2Cl)cc1)C(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 8/20 0.68
▸ MMEL1 Q495T6 6/20 0.54
▸ RORC P51449 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ PPARG P37231 2/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ACE P12821 2/20 0.38
▸ ACE2 Q9BYF1 1/20 0.38
▸ GPR34 Q9UPC5 1/20 0.38
▸ CTSS P25774 1/20 0.37
▸ CTSK P43235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768279 1.00 MME (0.68) MMEMMEL1RORCPTPN1PPARG
SCHEMBL6903314 1.00 MME (0.68) MMEMMEL1RORCPTPN1PPARG
SCHEMBL3776089 1.00 MME (0.68) MMEMMEL1RORCPTPN1PPARG
SCHEMBL1768280 0.89 MME (0.62) MMEMMEL1PTPN1PPARAMEN1
SCHEMBL1793637 0.89 MME (0.62) MMEMMEL1PTPN1PPARAMEN1
SCHEMBL1768282 0.89 MME (0.62) MMEMMEL1PTPN1PPARAMEN1
SCHEMBL3701727 0.85 MME (0.54) MMEMMEL1ACEGPR34
SCHEMBL3701729 0.85 MME (0.54) MMEMMEL1ACEGPR34
SCHEMBL16602086 0.84 MME (0.64) MMEMMEL1RORCMEN1MAPT
SCHEMBL15608113 0.82 MME (0.54) MMEMMEL1PPARGPPARAACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2735561-B1 Substituted carbamoylmethoxyacetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2016-07-20 — — EP disclosed
EP-2640375-B1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2016-05-18 — — EP disclosed
US-8993631-B2 Method of treating contrast-induced nephropathy NOVARTIS AG (CH) 2015-03-31 — — US disclosed
US-20140336194-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2014-11-13 — — US disclosed
US-8877786-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-11-04 — — US disclosed
EP-2735561-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors Novartis AG (CH) 2014-05-28 — — EP disclosed
EP-2501683-B1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS NOVARTIS AG (CH) 2014-04-23 — — EP disclosed
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-03-27 — — US disclosed
US-8642635-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-02-04 — — US disclosed
EP-2640375-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY Novartis AG (CH) 2013-09-25 — — EP disclosed
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-04-18 — — US disclosed
US-8377978-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-02-19 — — US disclosed
EP-2501683-A1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS Novartis AG (CH) 2012-09-26 — — EP disclosed
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-08-09 — — US disclosed
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-08-09 — — US disclosed
US-8222286-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-07-17 — — US disclosed
WO-2012065958-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2011-05-26 — — US disclosed
WO-2011061271-A1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS NOVARTIS AG (CH) 2011-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 485/4885RORC 4324/4885
US-20140336194-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME MME 3/4885MMEL1 118/4885RORC 4868/4885
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 485/4885RORC 4324/4885
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME MME 3/4885MMEL1 118/4885RORC 4868/4885
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 485/4885RORC 4324/4885
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 MME 1/4885MMEL1 493/4885RORC 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.